Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer

Hideki Katayama, Akio Hiraki, Keiichi Fujiwara, Keitaro Matsuo, Tadashi Maeda, Kenichi Chikamori, Daizo Kishino, Kazuo Tajima, Hiroshi Ueoka, Keisuke Aoe

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

The aim of this study was to investigate the prognostic value of hypermethylation of tumor suppressor genes in patients with non-small cell lung cancer (NSCLC). In samples from 34 lung patients with malignant pleural effusions, we used a methylation-specific polymerase chain reaction to detect aberrant hypermethylation of the promoters of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT), p16INK4a, ras association domain family 1A (RASSF1A), apoptosis-related genes, death-associated protein kinase (DAPK), and retinoic acid receptor ß (RARß).There is no association between methylation status of five tumor suppressor genes including MGMT, p16INK4a, RASSF1A, DAPK and RARß in pleural fluid DNA and clinicopathological parameters including clinical outcome. Aberrant promoter methylation of tumor suppressor genes in pleural fluid DNA could not be a valuable prognostic marker of NSCLC patients with malignant pleural effusion.

Original languageEnglish
Pages (from-to)221-224
Number of pages4
JournalAsian Pacific Journal of Cancer Prevention
Volume8
Issue number2
Publication statusPublished - 2007
Externally publishedYes

Keywords

  • MGMT - p16ink4a - RASSF1A - DAPK - rar - Malignant Pleural Effusion - Survival

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

Fingerprint

Dive into the research topics of 'Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this